| CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia (NCT04704323) | Catapult Therapeutics | 2021-09-10 |
| A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT02500407) | Genentech, Inc. | 2015-09-15 |
| Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) (NCT02292225) | SecuraBio | 2015-02-01 |
| Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (NCT02242942) | Hoffmann-La Roche | 2014-12-31 |
| A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (NCT01685892) | Genentech, Inc. | 2012-11-29 |
| A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia (NCT01609023) | Hoffmann-La Roche | 2012-04-01 |
| A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) (NCT01414205) | Genentech, Inc. | 2011-10-31 |
| A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia (NCT01263704) | Hoffmann-La Roche | 2011-07-17 |
| A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status (NCT01271010) | Hoffmann-La Roche | 2011-06-17 |
| A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON) (NCT01300247) | Genentech, Inc. | 2011-05-01 |
| A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status (NCT01283386) | Hoffmann-La Roche | 2011-04-27 |
| A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia (NCT01292603) | Hoffmann-La Roche | 2011-04-18 |
| An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia (NCT01488162) | Hoffmann-La Roche | 2011-04-04 |
| An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC) (NCT01224093) | Hoffmann-La Roche | 2010-10-01 |
| A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) (NCT01056510) | Hoffmann-La Roche | 2010-03-01 |
| A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) (NCT01178086) | Hoffmann-La Roche | 2010-02-22 |
| CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) (NCT02053610) | Hoffmann-La Roche | 2009-12-31 |
| CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) (NCT01998880) | Hoffmann-La Roche | 2009-12-22 |
| CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) (NCT01010061) | Hoffmann-La Roche | 2009-12-21 |
| An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (NCT01072240) | Hoffmann-La Roche | 2009-09-01 |
| A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia. (NCT00738374) | Hoffmann-La Roche | 2008-11-03 |
| An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia (NCT01395615) | Hoffmann-La Roche | 2008-10-01 |
| A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia (NCT00754650) | Hoffmann-La Roche | 2008-09-01 |
| A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia. (NCT00532129) | Hoffmann-La Roche | 2007-11-01 |
| A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia (NCT00431873) | Mirati Therapeutics Inc. | 2007-01-01 |
| A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) (NCT02533401) | Hoffmann-La Roche | 2006-02-01 |
| CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy (NCT02013817) | Hoffmann-La Roche | 2005-10-11 |
| Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00143065) | Ohio State University Comprehensive Cancer Center | 2005-08-01 |
| Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies (NCT00241358) | Washington University School of Medicine | 2004-05-01 |
| Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant (NCT00143845) | University of Michigan Rogel Cancer Center | 2003-04-01 |